Evidence - Based Claim Substantiation for Red Yeast Rice (RYR): A Narrative Review and Mock Submission Dossier

Arshiya Begum Amjad[1], Dhanshree Lakudkar[2], Yashmin Khan[3], Md. Quamruz Zafar[4]
[1]*Tamil Nadu Government Dental College and Hospital, Chennai, Tamil Nadu*
[2,3] *Clinivance Labs*
[4]*Director, Clinivance Labs*

***Abstract*—This project presents a structured mock dossier for claim substantiation of Red Yeast Rice (RYR) in alignment with the Food Safety and Standards Authority of India (FSSAI) guidelines. The dossier was developed across 15 modules, covering regulatory frameworks, nutritional composition, mechanisms of action, safety, clinical evidence, pharmacovigilance strategies, and identified research gaps. Eight peer-reviewed clinical and safety studies were critically analysed to evaluate the efficacy of RYR in lowering LDL cholesterol and its safety profile. Supporting evidence demonstrated LDL reductions of 15–34% in short-term randomized controlled trials, with nutrivigilance data from ~3.9 million consumers confirming overall safety when products are citrinin-free and standardized. While traditional use has long established RYR's cultural acceptance, modern regulatory substantiation requires product-specific clinical equivalence, labeling safeguards, and nutrivigilance oversight. The final proposed health claim — "Helps maintain healthy cholesterol levels when consumed as part of a balanced diet" — is scientifically supported, regulator-compliant, and consumer-oriented. This project highlights the importance of evidence-based claim substantiation and proposes directions for future research to strengthen regulatory confidence.**

***Index Terms*—Red Yeast Rice, FSSAI, claim substantiation, cholesterol, LDL, nutrivigilance, functional foods**

I. INTRODUCTION TO CLAIM SUBSTANTIATION

Every health claim you see on food packages or supplement bottles is basically a promise. The company is saying their product will do exactly what that label claims. But before any of those promises reach consumers, someone needs to prove they're true. This process — where companies back up their claims with real scientific proof - that's claim substantiation (Li et al., 2014*)*. And it's not something you can skip.

In India, this process falls under the Food Safety and Standards Authority of India, or FSSAI for short. Their job is to make sure companies aren't just making stuff up. Every health claim needs solid data behind it, and FSSAI goes through all of it before giving the thumbs up. They're trying to protect people from false claims while keeping things fair for businesses that play by the rules.

Here's how it typically works. Companies write out their claim in plain language — something clear that can be tested, not vague marketing language.

Then they gather up studies, safety reports, whatever scientific evidence supports what they're claiming. All of this gets put together in a file called a ***dossier,*** which basically contains everything regulators need to review. Each step gets the claim closer to official approval. This is only the beginning. Now that we understand the 'what' and 'why' of claim substantiation, the next module will introduce the primary regulatory body that governs this process in India — the FSSAI.



Figure 1 - Process of claim substantiation

II. OVERVIEW OF FSSAI AND HEALTH CLAIMS

When it comes to health claims on food and supplement labels in India, FSSAI is the one setting the rules. Their role is straightforward: keep health claims clear, evidence-based, and honest.

FSSAI sorts claims into a few buckets. Some are simple *nutrient function claims,* like saying calcium helps maintain strong bones. Others are *health claims,* such as a product supporting healthy cholesterol levels. There are also *disease risk reduction claims,* but these need very strong proof — because they suggest the product can lower the chance of developing a disease *(Li et al., 2014).*

For any of these to make it onto a label, companies must bring real evidence to the table — clinical studies, reviews, or safety data that hold up under scrutiny. If the proof isn't strong enough, the claim doesn't get cleared.

This system is there to protect people from misleading promises and to make sure everyone in the market plays fair. Understanding how the FSSAI evaluates claims gives us the context we need before we dive into red yeast rice and its cholesterol-related benefits in the next modules.

III. RED YEAST RICE: TRADITIONAL USE AND MODERN INTEREST

Red yeast rice isn't some new trend that just popped up. People in China have been using it for hundreds of years, way before anyone understood what made it work. Back then, they used it to colour food, but also noticed it seemed to help with digestion and blood flow. Nobody knew the science behind it — they just saw that people felt better after using it regularly.

In recent decades, however, researchers have explained why it might be effective. Red yeast rice has been found to contain something called *monacolin K*, that works much like statin drugs that doctors prescribe for high cholesterol *(D Heber et al., 1999).* That discovery got everyone's attention quickly. Here was this traditional food ingredient that might work similarly to prescription medication.These days, you can find red yeast rice supplements in stores across India and other countries. It's become popular with people who want a "natural" option for managing cholesterol, especially folks who can't handle regular statin drugs because of side effects *(Becker DJ et al., 2009)*. But this popularity creates a problem for regulators. Something that used to be just a cooking ingredient is now being marketed like medicine.

This shift from kitchen to medicine cabinet is exactly why we need proper claim substantiation. Just because something worked as a folk remedy doesn't mean companies can automatically make health claims about it. They need real clinical data to back up statements like *"helps maintain healthy cholesterol levels"* — and that's where things get complicated.

IV. NUTRITIONAL COMPOSITION OF RED YEAST RICE

Red yeast rice may look simply, but where it excels is its inner constitution. The rice is fermented using a special strain of yeast called *Monascus purpureus.* During fermentation, the rice turns a deep red and produces a series of bioactive molecules.

Most familiar is monacolin K, whose action is like a statin medication to lower cholesterol *(Li et al., 2014)*. But RYR is more than monacolin K. It is also packed with antioxidant pigments, cholesterol-blocking plant sterols, isoflavones with potential hormonal and heart-protective benefits, and traces of fatty acids and Fiber beneficial to the heart and gut *(Cicero AFG et al., 2023)*

Here is a simple breakdown of its key components:

Component	Potential Effects	Approximate Content
Monacolin K	Cholesterol reduction by inhibiting HMG-CoA reductase	Varies (2–10 mg per dose)
Pigments (e.g., monascorubrin)	Antioxidant and anti-inflammatory	Trace amounts
Sterols (e.g.,	Block intestinal cholesterol	~1–5% of fatty acid fraction

β-sitosterol)	absorption	
Isoflavones	Hormonal balance, cardiovascular support	Variable
Fatty acids & Fiber	Support heart health and digestion	~1–5% fatty acids, minor Fiber

Table 1 - Components of RYR

Actual content levels of these substances can significantly differ from one preparation to another, methodology notwithstanding. Such difference necessitates prudence by regulators: too little monacolin K may make a product ineffective, whereas excessive amounts may raise the risk of adverse effects.

Red yeast rice's very composition is what gives it both its potential benefit and its regulatory challenge — which is why robust scientific evidence is needed before allowing health claims

V. UNDERSTANDING CHOLESTEROL AND LDL

Cholesterol is also portrayed as an ugly substance, but nowhere near as ugly as everyone makes it out to be. It's necessary for making hormones and vitamin D, and for maintaining cell membranes *(Scott M Grundy et al., 2019)*. The problem arises when low-density lipoprotein (LDL) cholesterol, the "bad" cholesterol, is too high.

LDL is short for low-density lipoprotein. It's like delivery trucks that transport cholesterol throughout the body through the bloodstream. With too many delivery trucks driving around, they begin to deposit cholesterol in areas where it shouldn't be deposited, like the lining of arteries. The more it accumulates, the more it narrows the arteries, which subsequently restricts flow as well as makes an individual more susceptible to experiencing heart attack or stroke *(Scott M Grundy et al., 2019).*

HDL cholesterol or "good" cholesterol is also included. This type of material is something of a garbage truck as it travels through one's system to gather excess cholesterol and return it to the liver to be metabolized and excreted *(Scott M Grundy et al., 2019)*. Therefore, the main goal is not to take cholesterol away completely, Instead, the goal is to decrease LDL levels while maintaining sufficient HDL levels. There are several variables that influence the way our bodies process cholesterol, including diet, genetics, and lifestyle. Guidelines commonly consider LDL ≤100 mg/dL as a general goal for many adults; lower thresholds (≤70 mg/dL) are used for high-risk/secondary prevention *(Scott M Grundy et al., 2019).*

This equilibrium is why red yeast rice has been seen in cardiovascular well-being. Through decreasing levels of LDL cholesterol, it lessens arterial tension and contributes to whole cardiac operation *(Cicero AFG et al., 2023)* (*Banach M et al., 2024) (Liasi E et al., 2024)*



Figure 2 - Flowchart: Cholesterol Metabolism

VI. MECHANISM OF ACTION OF RED YEAST RICE

Red yeast rice generally achieves its action by inhibiting formation of cholesterol within the body. Monacolin K is its key active ingredient for this effect and is chemically identical to prescription statin drug lovastatin widely employed by physicians (Li et al., 2014; Cicero et al., 2023). Monacolin K achieves its effect by inhibiting an enzyme known as HMG-CoA reductase vital to liver synthesis of cholesterol.

By inhibiting this enzyme, monacolin K reduces the liver's capacity to synthesize cholesterol, thereby lowering LDL levels in blood vessels. (Cicero et al., 2023).

Consider it from this perspective: a reduction in the number of LDL particles circulating in your bloodstream leads to diminished chances for cholesterol to adhere to the walls of arteries, thereby contributing to plaque accumulation. This phenomenon aids in maintaining clearer arteries, alleviates some stress on the heart, and enhances overall blood circulation (Heber et al., 1999; Becker et al., 2009).

But red yeast rice doesn't stop there. It has other constituents beyond monacolin K like other monacolins, plant sterols, and pigments with antioxidant activities. They potentially can have ancillary benefits by inhibiting how much intestinal absorption is obtained by food for cholesterol and combating oxidative damage at the body level (Liasi et al., 2024; Narrative Review, 2025).

Because RYR acts like a statin, it can cause similar adverse effects (e.g., myalgia, rare liver enzyme elevations) in some users. Certain individuals are subject to muscle pains or, extremely rarely, hepatic concerns—especially when products are neither properly standardized nor quality controlled (Banach et al., 2024). For this reason, compliant dosing and appropriate follow-up are paramount to safety. The point is that RYR functions by essentially reducing your liver's manufacture of cholesterol to improve the ratio of good to bad cholesterol and to aid heart health over the long haul.



Figure 3 -Flowchart: Mechanism of action of RYR

VII. CLINICAL EVIDENCE: SHORT-TERM STUDIES

One of the most compelling arguments in favour of red yeast rice (RYR) as an option for lowering cholesterol arises from human clinical trials. Numerous studies have demonstrated that RYR can reduce LDL cholesterol levels within a matter of weeks when used consistently.

In one classic randomized trial, patients taking a commercial red yeast rice (RYR) product reduced their LDL cholesterol by approximately 22% after 12 weeks, a degree comparable with low-dose therapy with statins *(D Heber et al., 1999)*. These outcomes have been replicated in numerous other populations, including patients with intolerance to statins.

In such patients, RYR served as a tolerated, "naturally" derived alternative product that nonetheless accomplished clinically meaningful reductions in concentrations of LDL cholesterol *(Becker DJ et al., 2009)*.

Short-term trials are routinely positive and show a decrease in total cholesterol with occasional slight HDL cholesterol elevations, albeit with less dramatic effect *(Li et al., 2014)*. Most clinical trials used

proprietary/standardized preparations of RYR extracts providing 2–10 mg/day monacolin K — although product content can vary between preparations and this variability is important to note ***(Liasi et al., 2024; Cicero et al., 2023).***

The primary limitation is that such trials are usually of a duration of 4–24 weeks, so while they establish the efficacy of RYR in the immediate future, they do not adequately solve long-term consistency and safety concerns – issues addressed later in modules.

Study	*Population*	*Duration*	*Intervention (Monacolin K/day)*	*LDL Reduction*	*Other Findings*	*Sample size*
Heber et al., 1999	Adults with hypercholesterolemia	12 weeks	~10 mg	↓ ~22%	Total cholesterol↓; TG ↓	83
Becker et al., 2009	Statin intolerant patients	24 weeks	6 mg	↓ ~19%	Well tolerated, few side effects	62
Li et al., 2014 (Meta-analysis)	Heterogeneous designs (20 RCT)	4-24 weeks	3-10 mg	↓~15-34%	Well tolerated, few side effects	804

TG = Triglycerides

*Table 2 -Summary of Key Short-Term Clinical Trials on RYR*7.1 Strength of Evidence:Short-term clinical trials yield *moderate-to-high evidence* that RYR reduces LDL cholesterol by 20–30% within 8–12 weeks *(Heber et al., 1999; Becker et al., 2009).* The findings are extremely consistent with various populations, including those intolerants to statins. The sole significant limitation is that such trials are brief and do not have long-term outcomes or cardiovascular event reduction. However, the evidence strongly shows short-term effectiveness and the meta-analyses and the pooled data underpinning these results affirm this

VIII. CLINICAL EVIDENCE: META-ANALYSES AND REVIEWS

While single trials confirm LDL cholesterol can significantly be decreased through red yeast rice (RYR), meta-analyses and systematic reviews provide a general perspective of effectiveness across various populations.

A more recent large-scale meta-analysis of 13 randomized controlled studies concluded that RYR supplementation reduces LDL cholesterol by ~15–34%, across all studies with an average of 25% (*Li et al., 2014).* These findings were regardless of patient age and pre-treatment cholesterol level, and this reinforces confidence that RYR works in most individuals with mild to moderate hypercholesterolemia.

A more recent systematic review also confirmed these results and emphasized RYR's dose-dependency — higher monacolin K content produces larger reductions in LDL, but also requires stringent quality control not to over-dose *(Liasi et al., 2024).*

Recent narrative reviews validate that Red Yeast Rice (RYR) has been one of the most investigated nutraceuticals in lipid control and has equivalent lipid-reducing efficacy to low-dose statins and has an otherwise favourable safety profile, provided standardized products are taken *(Cicero et al., 2023; English, 2025).*

In summary, pooled evidence reveals RYR not to be an occasional outcome of some trials but an enduringly successful means to reduce LDL cholesterol in numerous studies, strengthening considerably the case for its assertion.

Review / Meta-analysis	Year	No. of Studies	Total Participants	Mean LDL Reduction	Key Notes
Li et al. (Meta-analysis)	2014	20 RCTs	~804	↓~15–34%	Consistent LDL reduction across populations
Liasi et al. (Systematic Review)	2024	12 RCTs	~700	↓~21–38%	Dose-dependent effect; stressed need for standardization
English (Narrative Review)	2025	—	—	Similar to low-dose statins	Comprehensive clinical overview
Cicero et al. (Narrative Review)	2023	—	—	Consistent benefit	Supports use in mild -to-moderate hypercholesterolemia

Table 3 - Summary of Meta-Analyses and Reviews on RYR

8.1 Strength of Evidence:*Strong evidence* of RYR-induced LDL lowering comes from many well-designed randomized controlled trials, two updated meta-analyses, and several narrative reviews. Effect size is uniform across trials (mean 25% LDL lowering) and reproducible in the general hypercholesterolemic and statin intolerant population *(Li et al., 2014; Becker et al., 2009)*. The most limiting factor is the brief duration of the
majority of trials (4–24 weeks), and therefore although the short-term efficacy is established, results at longer term such as a decrease in cardiovascular events need more studies *(Liasi et al., 2024).*

IX. THE SAFETY PROFILE OF RED YEAST RICE (RYR)

Red yeast rice (RYR) at usual doses is also generally considered safe, but it is essential to take stock of its safety profile—more so, in view of monacolin K content, which is chemically equivalent to lovastatin.

9.1 Adverse Effects:

Most common reported side effects are generally mild and comprise muscle pain and gastrointestinal upset (*Becker et al., 2009)*. However, life-threatening events such as elevations in liver enzymes or rhabdomyolysis happen very rarely and generally occur in supra-therapeutic or unintended doses *(Banach et al., 2024).*

Post-marketing nutrivigilance information in 3.9 estimated million consumers revealed occurrence of serious adverse events at an extremely low frequency, not significantly different from, or even less than, those observed for prescription statins at equivalent doses *(Banach et al., 2024).*

9.2 Product Quality and Standardization:

A key safety concern with RYR is product variability. Some commercially available supplements contain too little monacolin K (ineffective), while others exceed safe levels or contain contaminants such as citrinin — a mycotoxin that can harm the kidneys *(Liasi et al., 2024).* This is why regulatory oversight and quality

control testing are critical to ensure both safety and efficacy.

9.3 Drug Interactions and Special Populations:

Since it has functional similarity to statins, Red Yeast Rice (RYR) may experience potential interactions with some medications; e.g., CYP3A4 inhibitors can raise monacolin K concentrations in blood and cause an increased risk of muscle toxicity. Patients who have liver disease, pregnancy, and lactation patients also ought to steer clear of RYR *(Cicero et al., 2023).*

Source	Population / Sample Size	Adverse Events Reported	Key Findings
Becker et al. (2009)	62 statin intolerant patients (12 weeks)	Mild myalgia, GI upset	No serious events, well-tolerated
Banach et al. (2024)	Post-marketing, ~3.9 million users	<0.1% serious events	AE rate like low-dose statins; rare liver/muscle toxicity
Liasi et al. (2024)	11 RCTs, ~700 participants	Muscle pain >5%, transient LFT elevation	Dose-dependent effects, emphasized standardization
Cicero et al. (2023)	Narrative review	—	Advised avoidance in pregnancy/liver disease and highlighted need for citrinin-free products

Table 4 -Summary of Safety Data for RYR

Aspect	Details	Regulatory / Clinical Implication
Primary Benefit	↓ LDL cholesterol by 15–38% (comparable to low-dose statins)	Strong evidence supports use in mild-to-moderate hypercholesterolemia
Additional Benefit	Small ↑ HDL, ↓ Total cholesterol, antioxidant support	May contribute to overall cardiovascular risk reduction
Main Risks	Mild muscle aches, GI upset, rare liver enzyme elevation	Monitor for statin like side effects in sensitive populations
Product Quality Risks	Variability in monacolin K content; potential citrinin contamination	Need for standardization and quality testing
Mitigation Strategies	Use standardized, citrinin-free products; patient education; periodic LFT monitoring if used long term	Ensures benefit outweighs risk

Table 5 -Risk–Benefit Summary of Red Yeast Rice

X. REGULATORY CONCERNS AND PRODUCT VARIABILITY

Regulatory and quality matters are of first concern with any health-claim submission of the red yeast rice (RYR). A single entity pharmaceutical product differs from RYR since the latter is made from a host of manufacturers using a variety of strains, fermentation configurations, and extraction or post-processing techniques. These variables influence the amount of active monacolin K, the composition of other monacolins, and the risk of unwanted impurities, *e.g., the mycotoxin citrinin.* Because standard and specific formulations were used during the time of clinical trials, regulators will demand product-specific proof of a marketed product's comparability with one tested *(Li et al., 2014; Liasi et al., 2024).*

10.1 Key points regulators will focus on:

10.1.1 Monacolin K content and labelling:

Dossiers should state monacolin K per serving and per day and with established assay methods and Batch Certificates of Analysis (COA). Clinical evidence generally originates from products yielding ~2–10 mg monacolin K/day *(Liasi et al., 2024; Cicero et al., 2023).*

10.1.2 Citrinin Testing:

Citrinin is a nephrotoxic mycotoxin capable of contaminating fermented products; therefore, testing and limits must be established for each batch *(Liasi et al., 2024).*

10.1.3 Manufacturing & consistency:

Details of strain, key process steps, GMP compliance, and batch-to-batch stability of monacolin K are required. *(Cicero et al., 2023; Liasi et al., 2024).*

10.1.4 Product equivalence:

When clinical trials use a proprietary extract, the dossier needs to show equivalence of the marketed product with that clinical product or provide product-specific clinical evidence. *(Cicero et al., 2023).*

10.1.5 Adulteration and impurities screens:

Present evidence of undeclared drugs and impurity/contaminant analysis results *(Li et al., 2014; Cicero et al., 2023).*

Issue	Why it matters	Minimum dossier evidence
Monacolin K variability	Determines whether clinical effect is reproducible	Quantitative assay method; COAs for ≥3 batches; label mg/serving and mg/day. (Li et al., 2014)
Citrinin contamination	Safety (nephrotoxin)	Batch citrinin test reports; method & LOQ; statement marketed batches are below detection/regulatory limit. (Liasi et al., 2024)
Manufacturing differences	Alters active/impurity profile	Manufacturing summary, GMP statement, stability data showing consistent monacolin K across batches. (Cicero et al., 2023)
Product equivalence	Trial product ≠ retail product unless proven	Bridging data or product-specific clinical evidence; exact trial dose replicated. (Li et al., 2014)
Adulteration / impurities	Regulatory reclassification risk	Impurity and adulterant screen; certificate of non-adulteration. (Cicero et al., 2023)

Table 6 – Regulatory issues & minimum dossier evidence



Figure 4 - Minimum quality evidence pathway

XI. COMPARISON WITH STATINS

This module compares RYR (standardized products) and prescription statins in terms of efficacy, mechanism, safety, and regulatory reliability. It aims to provide clarity and usefulness for dossier reviewers.

11.1 Mechanism:

RYR: Active monacolin K which is chemically identical to lovastatin and inhibits the enzyme HMG-CoA reductase — the same molecular target as statin drugs. Accordingly, we see statins like LDL lowering. *(Li et al., 2014; Cicero et al., 2023)*

Statins: Prescription statins are single-entity, dose-standardized drugs with well-characterized pharmacology and clinical outcomes. *(Grundy et al., 2019)*

11.2 Efficacy (short-term LDL lowering):

RYR (standardized formulations): Meta- analyses and randomized studies report ~15–38% reduction of LDL at 4–24 weeks *(Li et al., 2014; Cicero et al., 2023)*

Statins: Low-dose statins typically lower LDL by about ~20–30%; higher intensities further lower LDL *(Grundy et al., 2019)*

11.3 Safety & Monitoring:

RYR: Side effects noted in RYR trial studies are myalgia and gastrointestinal upset with rare elevations in liver enzymes. Reported serious safety issues are often linked to product inconsistency as much as possible contaminants, like citrinin, or undeclared active ingredients. *(Becker et al., 2009; Banach et al., 2024; Liasi et al., 2024)*

Statins: Adverse effects are well documented in long-term RCTs, providing a clearer picture of risk profiles; directions for monitoring liver function and muscle symptoms determined. *(Grundy et al., 2019)*

11.4 Evidence regarding cardiovascular outcomes:

RYR: Lipoprotein endpoints are mostly covered as evidence. Few long-term results of region-specific, partially purified products (i.e., Xuezhikang) suggest outcome efficacy but cannot be extrapolated immediately across the entire OTC RYR spectrum. Product-specific outcome evidence exists for some proprietary extracts; generalization to all RYR products is not appropriate without equivalence data. *(Cicero et al., 2023; English, K., 2025)*

Statins: Strong consistent evidence from large RCTs and meta-analyses shows MI, stroke and death reduction. *(Grundy et al., 2019)*

11.5 Practical Dossier note:

If a product manufacturer wants to say "helps maintain healthy cholesterol levels," the dossier should show that the marketed product is an identical copy of the clinical product (monacolin K formulation, COAs, citrinin-free status). If you don't do that, you

cannot generalize study results from one proprietary extract of a different product

Aspect	Red Yeast Rice (Standardized)	Prescription Statins
LDL reduction	~15–38% (Li et al., 2014; Cicero et al., 2023)	~20–30% at low dose; higher with potent statins (Grundy et al., 2019)
Mechanism	Monacolin K inhibits HMG-CoA reductase (lovastatin like)	Statins inhibit HMG-CoA reductase; well-studied PK/PD
Safety	Mild AEs, rare liver enzyme elevation; risk rises with poor-quality products (Banach et al., 2024)	Well-characterized AE profile; routine monitoring recommended
Outcome evidence	Limited/generalizable only for certain standardized extracts	Large RCTs & meta-analyses prove CV event reduction
Quality concern	Requires COAs, citrinin testing, dose standardization	Fully regulated, pharmaceutical-grade manufacturing

Table 7 – Red Yeast Rice Vs Prescription Statins



Figure 5 - RYR vs. statin intensities for LDL reduction

XII. ROLE OF PHARMACOVIGILANCE (PV) FOR SUPPLEMENTS (NUTRIVIGILANCE)

Principles of pharmacovigilance also apply to supplements — also called nutrivigilance. For a post-market plan and a dossier, both regulators demand a pre-market summary of safety and a viable post-marketing plan to document adverse events, identify signals and react to safety problems *(Banach et al., 2024).*

12.1 Core elements for a pharmacovigilance plan:

12.1.1 Pre-marketing safety summary:

Condense safety data from clinical trials (all RCTs utilized in evidence), laboratory monitoring results and any serious events known from trials. *(Becker et al., 2009; Li et al., 2014).*

12.1.2 post-marketing surveillance strategy:

Set up AE intake channels (multiple), case handling (ICSRs), periodic safety reports (frequency as per local regulator), detection of signal and risk minimization (label updates, batch recall as needed). With ~3.9 million consumers' post marketing data

available, these reports provide a benchmark to understand the types and frequencies of adverse events in real-world use, though comparisons with statins should be made cautiously since monitoring systems differ. *(Banach et al., 2024).*

12.1.3 Risk mitigation that values product quality:
As product variation and citrinin are the principal safety determinants, frequent testing of batches and publicly accessible advice (e.g., "product batch tested for citrinin: yes/no") should form part of the risk management plan *(Liasi et al., 2024).*

Activity	Why	Minimum deliverable for dossier
AE intake & triage	Capture consumer/clinician reports quickly	Describe intake channels (phone, web, email) and triage SOPs
ICSR processing	Standardized case handling and MedDRA coding	Provide sample ICSR form + processing workflow
Periodic safety reports	Aggregate safety trends for regulator	PSUR (or equivalent) schedule and sample template
Signal detection	Identify unexpected AEs or trends early	Describe methods: trend analysis, disproportionality
Root-cause investigation	Link AEs to specific batches or product issues	COA review, batch history, investigation report
Risk minimization & communication	Reduce future harm, inform users & clinicians	Label updates, Dear HCP letters, recall SOPs

Table 8 – Practical PV / Nutrivigilance Activities for an RYR Product



Figure 6 - Flowchart – Nutrivigilance Lifecycle

XIII. DETERMINING RESEARCH GAP

Despite the extensive body of studies on red yeast rice (RYR), several unanswered questions persist that cast doubt on the robustness of health claims and regulatory confidence. Pinning down these lacunae enables reviewers to know where additional evidence is required and accordingly enhances dossier credibility.

13.1 Major Evidence Gaps:

13.1.1 Product-Specific Clinical Information:

Most meta-analyses and clinical trials employed proprietary red yeast rice (RYR) extracts, e.g., Xuezhikang. Extrapolation to other commercial preparations is not valid unless equivalence is demonstrated. *(Cicero et al., 2023).*

13.1.2 Long-Term Safety Evidence:

Few trials extend beyond 12 months. Longitudinal multi-year studies would be required to ensure safety regarding muscle toxicity, rise in liver enzymes, and rare side reactions. *(Banach et al., 2024)*

13.1.3 Post-Marketing Harmonization:

Although data from ~3.9 million consumers are provided, post-marketing surveillance across the globe is not harmonized. Common databases and harmonized ICSR reporting would improve safety signal detection. *(Banach et al., 2024)*

13.1.4 Dose-Response Clarity:

Clinical trial dosing was between 2–10 mg/day monacolin K. *(Liasi et al., 2024)* Definitive lowest effective dose and best safety ceiling are needed, especially for high-risk or polypharmacotherapy patients.

13.1.5 Cardiac Endpoint Information:

While most evidence focuses on LDL endpoints *(Li et al., 2014),* some reviews report benefits in hard cardiovascular outcomes like MI and stroke with specific extracts *(Cicero et al., 2023).*

Gap Area	Current Situation	Why It Matters	Future Research Priority
Product-specific data	Trials use proprietary RYR extracts	Cannot generalize results to all OTC products	Bridging studies proving equivalence
Long-term safety	Few >12-month studies	Limited confidence for chronic use	Multi-year RCTs with lab monitoring
Harmonized AE reporting	Post-marketing data fragmented	Global signal detection less reliable	Shared nutrivigilance database
Dose-response clarity	Dose range 2–10 mg/day	Uncertainty on minimum effective dose	Controlled trials defining dose curve
Cardiovascular outcomes	Few outcome RCTs	Regulators cannot approve CV risk reduction claims	Large outcome trials with marketed product

Table 9 – Summary of Research Gaps

XIV. FUTURE DIRECTIONS FOR RESEARCH

Following on from the identified research gaps in Module 13, this step defines some detailed next steps that could strengthen the evidence base and improve regulatory confidence about red yeast rice (RYR) products. Laying out a future research agenda demonstrates adherence to scientific standards and concern about protecting the public.

14.1 Priority Areas for Future Research:

14.1.1 Product Equivalence & Bridging Studies:

Schedule bioequivalence or bridging studies between proprietary trial products, such as Xuezhikang, and commercialized supplements.

Standardize tests for monacolin K content and submit impurity profiles to make them more clinically relevant. *(Cicero et al., 2023)*

14.1.2 Long-Term Safety Registries:
Establish prospective registries for consumers using the product for ≥3 years, with monitoring of liver function and muscle enzymes.
Capture unexpected events such as rhabdomyolysis or drug interactions to permit informed decisions regarding risk management. *(Banach et al., 2024)*
14.1.3 Global Nutrivigilance Harmonization:
Develop shared nutrivigilance systems to improve global signal detection, building on practices in *(Banach et al., 2024)*, potentially adapting standards like ICH for consistency.
14.1.4 Dose-Response and Special Populations:
Focus on statin intolerant patients for dose optimization *(Liasi et al., 2024)*, with future trials needed for other groups like the elderly or those with polypharmacy.
14.1.5 Cardiovascular Outcome Trials:
Carry out multicentre, randomized, endpoint-driven trials comparing RYR vs. placebo and vs. statins for outcomes such as MI, stroke, and CV death. *(Li et al., 2014; Cicero et al., 2023)*

Research Area	Objective	Suggested Study Design
Product equivalence	Show marketed product matches trial product	Bridging study with assay validation & impurity profiling
Long-term safety	Monitor rare AEs & lab markers	3–5-year prospective registry
AE reporting harmonization	Improve global signal detection	Shared post-marketing AE database
Dose-response clarity	Find minimum effective & maximum safe dose	Multi-arm RCT with dose titration
Cardiovascular outcomes	Demonstrate clinical benefit beyond LDL	Large multicentre RCT (MACE endpoints)

Table 10 – Recommended Future Research Directions



Figure 7 - Flowchart – Roadmap for Strengthening Evidence

XV. CONCLUSION AND CLAIM JUSTIFICATION

This final module integrates the evidence from Modules 1 to 14 and provides an unmistakable, regulator-friendly rationale for the intended health claim. Moreover, it includes suggested labeling and consumer instruction to enable safe and transparent use. This serves as a mock submission dossier to demonstrate compliance with FSSAI health claim approval standards.

15.1 Proposed Claim:

"Helps maintain healthy cholesterol levels when consumed as part of a balanced diet."

This is consistent with FSSAI's framework for health maintenance claims. It avoids disease-treatment language and is supported by the evidence base reviewed in this dossier.

15.2 Summary of Evidence:

Across meta-analyses, RCTs, and post-marketing data, standardized red yeast rice (RYR) supplements that contain verified monacolin K reduce LDL by approximately 15–38% at 4–24 weeks, comparable to low-dose statins *(Li et al., 2014; Cicero et al., 2023).* Adverse data from RCTs and ~3.9 million consumer-years of spontaneous post-marketing surveillance confirm rare, predominantly mild adverse experiences *(Becker et al., 2009; Banach et al., 2024)*. Key safety issues — muscular-related complaints, elevations of liver enzymes, and citrinin contamination — are manageable by quality control measures, judicious labeling, and monitoring.

Evidence Layer	Supporting Data
Clinical Evidence	RCTs, meta-analyses showing 15–38% LDL reduction
Safety Data	RCT adverse event profiles + post-marketing nutrivigilance (~3.9M consumers)
Product Equivalence	Requires COA for monacolin K, citrinin-free status, bridging studies if using a non-trial extract
Regulatory Safeguards	Labeling compliance, risk minimization steps, physician guidance for high-risk users

Table 11 – Regulatory Safeguards (Evidence Pyramid)

Required Element	Rationale
Monacolin K content per serving	Ensures transparency and allows dose verification (Li et al., 2014).
Citrinin-free statement	Required to mitigate nephrotoxicity risk (Banach et al., 2024).
Usage guidance	"Consume as part of a balanced diet" – aligns with FSSAI's requirement to avoid medical claims.
Caution for statin users	Alerts consumers on possible additive effects or drug interactions (Liasi et al., 2024).
Batch number + QR for COA	Provides traceability and consumer confidence.

Table 12 – Recommended Labeling Elements

15.3 Consumer Guidance:

- Recommended for adults with borderline elevation of LDL cholesterol.
- Should not replace statins that are given by doctors.
- Not advisable for pregnant, lactating women, nor for patients with active liver disease unless cleared by a doctor.
- Talk with your doctor if you experience muscle soreness or dark urine.

15.4 Justification:

The statement is true, not misleading, and suitable for the evidence that exists.

The proposed dossier comprises standardized clinical evidence, product-specific data, and a post-marketing plan, thereby fulfilling the requirements set forth by FSSAI for health claims. This balanced approach maximizes public benefit while protecting consumers through quality, labeling, and nutrivigilance safeguards. While the evidence supports the claim, limitations such as small sample sizes and product variability *(Heber et al., 1999; Li et al., 2014)* underscore the need for standardized RYR products and further large-scale RCTs.

Figure 8 -Claim Justification Flowchart – Stepwise Approach

This flowchart shows the stepwise logic regulators follow — from gathering evidence and quality data to claim approval and responsible consumer use — making Module 15 a strong, dossier-ready conclusion.

REFERENCES WITH LINKS

[1] Heber, D., Yip, I., Ashley, J. M., Elashoff, D. A., Elashoff, R. M., & Go, V. L. W. (1999). Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/9989685/

[2] Becker, D. J., et al. (2009). Red yeast rice for dyslipidaemia in patients intolerant to statins: a randomized trial. https://pubmed.ncbi.nlm.nih.gov/19528562/

[3] Li, Y., et al. (2014). A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidaemia. https://pubmed.ncbi.nlm.nih.gov/24897342/

https://pmc.ncbi.nlm.nih.gov/articles/PMC4045580/

[4] Cicero, A. F. G., et al. (2023). Red yeast rice for improvement of lipid profiles. Nutrients. https://pubmed.ncbi.nlm.nih.gov/37242171/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10221652/

[5] Liasi et al., 2024 Monacolin K supplementation meta-analysis and safety review (2024). Medicina de Familia – SEMERGEN. https://www.elsevier.es/en-revista-medicina-familia-semergen-40-articulo-monacolin-k-supplementation-in-patients-S1138359323002368

[6] Banach, M., et al. (2024, June). Post marketing nutrivigilance of red yeast rice: Updated safety data in ~3.9 million consumers. Archives of Medical Science. https://doi.org/10.5114/aoms/190111

[7] English, Kevan. (2025, September). Red yeast rice with monacolin K for the improvement of hyperlipidaemia: A narrative review. World Journal of Clinical Cases. https://pubmed.ncbi.nlm.nih.gov/40881894/ 10.12998/wjcc. v13.i27.105415

[8] Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. https://pubmed.ncbi.nlm.nih.gov/30586774/10.1161/CIR.0000000000000625